Phase II Trial of Rituximab and Short Duration Chemotherapy Followed by Zevalin as First-Line Treatment for Patients With Low Grade Follicular Non-Hodgkin's Lymphoma
Upon determination of eligibility, patients will be receive:
- Rituxan + CHOP or CVP + Ibritumomab Tiuxetan
Patients who are considered medical candidates for doxorubicin should receive CHOP
chemotherapy (Cyclophosphamide, doxorubicin, vincristine and prednisone). Patients who are
not considered medical candidates for doxorubicin should receive CVP chemotherapy
(Cyclophosphamide, Vincristine, and prednisone)
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Overall clinical response rate
John D. Hainsworth, MD
Principal Investigator
Sarah Cannon Research Institute
United States: Food and Drug Administration
SCRI LYM 22
NCT00193440
April 2002
January 2009
Name | Location |
---|